

Advanced Abdominal & Gastrointestinal Cancer Solutions



About



Vision

Focused on unmet needs in cancer treatment, particularly in abdominal/GI cancers through novel treatments and diagnostic technologies, and dramatically improve the survival of these patients

Partners IP & Partners

Proprietary and licensed technology from MD Anderson Cancer Center, Stanford University, and Rice University

PEREGRINE







SIBF ^{(†}





Technology

Treatment - Making radiotherapy available for pancreatic cancer patients by using protection prior to applying radiation

Diagnostic & Monitoring - Detecting pancreatic, colon, and stomach cancer cells by Implementing antibodies detecting newly discovered specific markers ڲٛڔؖۺ

A Technology Platform

Technology Platform applicable to treatments and diagnostics of other gastrointestinal tract cancers



The Problem

No Early Detection Methods

Only 10-20% are surgical candidates

due to location of the tumor and its spread

Tumor is typically not controlled by chemotherapy

Radiation therapy can sometimes be used to approximate surgery

High radiotoxicity

to adjacent organs (specifically the duodenum)

no protection to the intestines

when delivering higher doses of targeted radiation for pancreatic tumors) makes effective radiation impractical

Xerient presents a novel approach that opens the door for the use of radiation in the treatment of pancreatic cancer patients




Our Therapeutic Solution

Based on revolutionary collaborative research between a leading-expert in Pancreatic Cancer Treatment – Dr. Cullen Taniguchi of MD Anderson Cancer Center and world reknowned chemist - Prof. James Tour of Rice University



Repurposing of FDA Approved Prodrug

Utilized for other applications and FDA-approved for intravenous (IV) administration





Delivering the appropriate tumoricidal dose of radiation without inducing duodenal destruction



*Oral Administration of the drug is clinically safe


Our Diagnostic Solution - XR10 & XR15 Monoclonal Antibody

- XR10 targets CD66c, an aggression molecule used by cancer cells for invasion and dissemination leading to metastasis
- The research and development work on XR10 have been conducted by industry and academia and supported by prestigious grant awards amounting for over \$20M
- Major effort developing XR10 as a drug. Open opportunity as a diagnostic and monitoring tool


- XR10 was tested in 150 human tissue samples where it demonstrated extremely high specificity (>90%)
- IP protects the biological, structural and attributes of the antibody and utilizing it alone and in connection to additional antibodies for enhanced results



THERAPEUTICS ROADMAP



DIAGNOSTICS ROADMAP





Conclusion

Targeting unmet needs in the cancer space

Building the company on proven technologies

based on solid science and advanced research

Repurposing of FDAapproved drug

(not development of a new one), oral administration of the drug already proven clinically safe

Strong and experienced

management with support of industry leaders on BOD and SAB

Received in August 2022 the very lucrative and non-diluting CPRIT grant of \$3M

Funded by two leading seed stage VC, committed to participate in follow on rounds

Initiating human studies in early 2023 for the therapeutic product, with potential regulatory approval of the diagnostic tool by 2024

Seeking additional \$3M to fund the company through Phase IIa and complete the diagnostic development (\$3M secured from CPRIT (grant) in October 2022)





Advanced Abdominal & gastrointestinal Cancer Solutions

Thank You.